4108Background: Conventional chemotherapy (CT) for advanced pancreatic cancer (PC) is associated with dismal response rates and poor survival. Arming anti-CD3 activated T cells (ATC) with anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) makes every ATC into a non-MHC-restricted EGFR-specific cytotoxic T lymphocyte. Engagement of CD3 on T cells and EGFR on PC cell lines leads to cytokine secretion, proliferation, cytotoxicity by ATC, and inhibition of tumor growth. Methods: We report on 9 LAPC and MPC patients (pts) (5 phase I and 4 phase I/II pts). In our phase I study at Karmanos Cancer Institute (KCI) on NCT0140874, EGFRBi-armed T cells (EGFR BATs) were used to target EGFR in 5 pts with unresectable or metastatic PC in a phase I dose escalation involving 3 weekly infusions of 10, 20, and 40 x 109 BATs per infusion followed by a booster infusion 3 months later for up to 80 x 109 BATs if they were stable or better. In a phase II study performed at KCI on NCT02620865 and continued at the University of Vir...
15 February 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Calvin X. Geng, Anuragh R. Gudur, Jagannath Kadiyala, Daniel S. Strand, Vanessa M. Shami, Andrew Y. Wang, Alexander Podboy, Tri M. Le, Matthew Reilley, Victor Zaydfudim, Ross C.D. Buerlein. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.23-136